Clinical trials: Glucocorticoids
Polymyalgia Rheumatica
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Patients are treated with infusions of Tocilizumab (TCZ) or placebo for 5 months. Clinical evaluation is performed using PMR-AS.
- Trial name
- NCT02908217
- Testing
- Tocilizumab
- Where
- 17 sites in France
- Volunteers
- 113 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis
Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis
OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after glucocorticoid treatment with or without methotrexate. II.
- Trial name
- NCT00004686
- Testing
- methotrexate, prednisone
- Volunteers
- 300 people
- Sponsor
- The Cleveland Clinic
Phobic Disorders, Phobias
Glucocorticoid Treatment for Social Phobia
Social phobia is the third most common psychiatric disorder besides depression and alcoholism. Several studies have demonstrated the efficacy of cognitive-behavioral therapy in the treatment of social phobia.
- Trial name
- NCT01574014
- Testing
- CBGT, Hydrocortisone
- Where
- Switzerland
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Chronic Graft Versus Host Disease
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
This study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and…
- Trial name
- NCT04944043
- Testing
- TQ05105 Tablet
- Where
- 12 sites in China
- Volunteers
- 45 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Osteoporosis
Percutaneous Vertebroplasty Versus Conservative Treatment in GIOPVCF
Based on the case reports and other literature, the investigators hypothesize that using PVP for treating GIOPVCF is associated with increased risk of vertebral refractures and does not provide further benefits compared to…
- Trial name
- NCT03330340
- Testing
- Percutaneous Vertebroplasty
- Volunteers
- 106 people
- Sponsor
- Peking University First Hospital
Body Composition, Beneficial, Paresis
Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health
About two-thirds of adults in the United States are overweight or obese with likely adverse health consequences. A Moderate weight loss by dieting and exercise is recommended to improve health.
- Conditions
- Body Composition, Beneficial, Paresis, Impaired Glucose Tolerance
- Trial name
- S38 (NCT02066948)
- Testing
- wt loss, Meal Pattern, even
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Purdue University
Aortic Dissection
Glucocorticoid on the Prognosis of TEVAR
To explore the potential prognostic effect of glucocorticoid on the postoperative aorta-related adverse events after aortic dissections patients underwent thoracic endovascular aortic repair (TEVAR), glucocorticoid (30mg/kg) will…
- Trial name
- NCT02523300
- Testing
- TEVAR, Glucocorticoids, saline
- Volunteers
- 240 people
- Sponsor
- Changhai Hospital
Osteoporosis
A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)
This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of single doses of odanacatib in mature adolescents and young adults who are currently receiving glucocorticoid therapy.
- Trial name
- NCT01630616
- Testing
- Odanacatib
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Adult Glucocorticoid Excess, Adult Adrenal Insufficiency
Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)
The excess of glucocorticoid, whether endogenous or exogenous, results in Cushing's syndrome, associating a particular distribution of fats (accumulation in the face and trunk), a decrease in the thickness of the muscles…
- Trial name
- CUSHINGOMICS (NCT04840693)
- Testing
- Biological samples, Complications
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants
This Phase IIIb/IV, two-arm, randomized, double-blind, placebo-controlled, parallel-group, international, multicenter trial compares the change in disease activity (as assessed by Disease Activity Score in 28 joints [DAS28]…
- Trial name
- NCT02573012
- Testing
- Prednisone, Tocilizumab
- Where
- 39 sites in France, Germany and 4 more
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche
PTSD - Post Traumatic Stress Disorder
Initial Study Sesting Efficacy and Tolerability of PT150 for PTSD in Veterans
The purpose of this study is to test the drug PT150, which blocks glucocorticoid receptor (GR) signaling, for treatment of PTSD in Veterans, and establish a safety and efficacy profile that will inform the design of future…
- Trial name
- NCT07187011
- Testing
- PT150
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- San Diego Veterans Healthcare System
Glucocorticoids Toxicity, COVID-19
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
The goal of this interventional study is to evaluate the pharmacokinetics, safety, and tolerability of 101-PGC-005 in healthy, adult, human subjects.
- Conditions
- Glucocorticoids Toxicity, COVID-19, Infectious Disease, Virus Diseases
- Trial name
- NCT05619770
- Testing
- 101-PGC-005
- Where
- India
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- 101 Therapeutics
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoidosis
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis
For pulmonary sarcoidosis, the initial dose recommended by the joint statement of the American Thoracic Society (ATS), European Respiratory Society (ERS), and The World Association of Sarcoidosis and Other Granulomatous Disorders…
- Trial name
- SARCORT (NCT03265405)
- Testing
- Low dose prednisolone, Medium dose prednisolone
- Where
- India
- Volunteers
- 86 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Prenatal Stress
Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure
The rapidly spreading coronavirus Covid-19 pandemic is a major concern worldwide and Italy is at the forefront of this emergency.
- Trial name
- MOM-COPE (NCT04540029)
- Testing
- Maternal stress
- Where
- Italy
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Healthy Adults
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated agonists of the glucocorticoid…
- Trial name
- NCT02767089
- Testing
- Prednisone
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Effect of Glucocorticoid on Exogenous Insulin Antibody Syndrome
Diabetic patients who have long-term insulin used can product antibody against exogenous insulin, the investigators named this condition Exogenous insulin antibody syndrome (EIAs).
- Trial name
- NCT04357392
- Testing
- Prednisone
- Volunteers
- 20 people
- Sponsor
- chenfengling
Eosinophilia, Hypereosinophilic Syndrome
Steroid Treatment for Hypereosinophilic Syndrome
Background: Hypereosinophilic syndrome (HES) is a disorder in which the body has too many eosinophils (a type of white blood cell). Too many eosinophils in HES can cause damage to the heart, nerves, or skin.
- Conditions
- Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder, Hematologic Diseases
- Trial name
- NCT01524536
- Testing
- prednisone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alcoholism
The Stress-Hormone System in Alcohol-Dependent Subjects
This study, conducted at the University of Texas Southwestern Medical Center and the Parkland Hospital in Dallas, will examine the stress hormone system of alcohol-dependent people.
- Trial name
- NCT00536146
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pemphigus Vulgaris
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
The purpose of this 12-month study was to determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris.
- Trial name
- NCT00429533
- Testing
- Dapsone
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Jacobus Pharmaceutical